Article and Video CATEGORIES

Cancer Journey

Search By

Gladys M. Rodriguez recently completed her hematology/oncology fellowship at Stanford in Palo Alto, California. She has just started her first job as an Assistant Professor of Medicine in Oncology/Hematology at Northwestern Feinberg School of Medicine specializing in gastrointestinal malignancies.

She completed her medical degree at Yale School of Medicine followed by an Internal Medicine residency at University of California, San Francisco. She holds a master’s degree in Epidemiology and Clinical Research from Stanford.

Program: Patient Education Ambassadors 2023-24
AlexandraGBeneke
The 2023-2024 GRACE Patient Education Ambassadors discuss topics in a variety of cancers, from screening and treating prostate cancer to aiding in the cost of cancer treatment.
Author
Gladys M Rodriguez MD, MS - Guest Faculty
Image
Patient Education Ambassadors 2023-24

 

Dr. Gladys Rodriguez and Hannah Manella, RD, discuss addressing nutritional concerns of patients who are undergoing cancer care.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on